Literature DB >> 34786940

Identification of Inhibitors of Fungal Fatty Acid Biosynthesis.

Christian DeJarnette1, Chris J Meyer2, Alexander R Jenner2, Arielle Butts3, Tracy Peters3, Martin N Cheramie2, Gregory A Phelps2,4, Nicole A Vita1, Victoria C Loudon-Hossler2, Richard E Lee2, Glen E Palmer3.   

Abstract

Fungal fatty acid (FA) synthase and desaturase enzymes are essential for the growth and virulence of human fungal pathogens. These enzymes are structurally distinct from their mammalian counterparts, making them attractive targets for antifungal development. However, there has been little progress in identifying chemotypes that target fungal FA biosynthesis. To accomplish this, we applied a whole-cell-based method known as Target Abundance-based FItness Screening using Candida albicans. Strains with varying levels of FA synthase or desaturase expression were grown in competition to screen a custom small-molecule library. Hit compounds were defined as preferentially inhibiting the growth of the low target-expressing strains. Dose-response experiments confirmed that 16 hits (11 with an acyl hydrazide core) differentially inhibited the growth of strains with an altered desaturase expression, indicating a specific chemical-target interaction. Exogenous unsaturated FAs restored C. albicans growth in the presence of inhibitory concentrations of the most potent acyl hydrazides, further supporting the primary mechanism being inhibition of FA desaturase. A systematic analysis of the structure-activity relationship confirmed the acyl hydrazide core as essential for inhibitory activity. This collection demonstrated broad-spectrum activity against Candida auris and mucormycetes and retained the activity against azole-resistant candida isolates. Finally, a preliminary analysis of toxicity to mammalian cells identified potential lead compounds with desirable selectivities. Collectively, these results establish a scaffold that targets fungal FA biosynthesis with a potential for development into novel therapeutics.

Entities:  

Keywords:  Candida auris; acyl hydrazide; antifungal; fatty acid synthesis; mucormycosis

Mesh:

Substances:

Year:  2021        PMID: 34786940      PMCID: PMC8670506          DOI: 10.1021/acsinfecdis.1c00404

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.578


  58 in total

1.  Architecture of a fungal fatty acid synthase at 5 A resolution.

Authors:  Simon Jenni; Marc Leibundgut; Timm Maier; Nenad Ban
Journal:  Science       Date:  2006-03-03       Impact factor: 47.728

Review 2.  Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

Authors:  Joshua B Parsons; Charles O Rock
Journal:  Curr Opin Microbiol       Date:  2011-08-20       Impact factor: 7.934

Review 3.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

Review 4.  Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

Authors:  J L Vincent; E Anaissie; H Bruining; W Demajo; M el-Ebiary; J Haber; Y Hiramatsu; G Nitenberg; P O Nyström; D Pittet; T Rogers; P Sandven; G Sganga; M D Schaller; J Solomkin
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

5.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

6.  Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

Authors:  Bart Jan Kullberg; Claudio Viscoli; Peter G Pappas; Jose Vazquez; Luis Ostrosky-Zeichner; Coleman Rotstein; Jack D Sobel; Raoul Herbrecht; Galia Rahav; Sutep Jaruratanasirikul; Ploenchan Chetchotisakd; Eric Van Wijngaerden; Jan De Waele; Christopher Lademacher; Marc Engelhardt; Laura Kovanda; Rodney Croos-Dabrera; Christine Fredericks; George R Thompson
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

7.  CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.

Authors:  Jodi A Laakso; Robert Raulli; Gail E McElhaney-Feser; Paul Actor; Ted L Underiner; Brian J Hotovec; Ursula Mocek; Ronald L Cihlar; Sheldon E Broedel
Journal:  J Nat Prod       Date:  2003-08       Impact factor: 4.050

8.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

9.  Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans.

Authors:  Deming Xu; Susan Sillaots; John Davison; Wenqi Hu; Bo Jiang; Sarah Kauffman; Nick Martel; Pam Ocampo; Chanseok Oh; Steve Trosok; Karynn Veillette; Hao Wang; Minghui Yang; Li Zhang; Jeffrey Becker; Charles E Martin; Terry Roemer
Journal:  J Biol Chem       Date:  2009-06-01       Impact factor: 5.157

10.  Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Authors:  Visesato Mor; Antonella Rella; Amir M Farnoud; Ashutosh Singh; Mansa Munshi; Arielle Bryan; Shamoon Naseem; James B Konopka; Iwao Ojima; Erika Bullesbach; Alan Ashbaugh; Michael J Linke; Melanie Cushion; Margaret Collins; Hari Krishna Ananthula; Larry Sallans; Pankaj B Desai; Nathan P Wiederhold; Annette W Fothergill; William R Kirkpatrick; Thomas Patterson; Lai Hong Wong; Sunita Sinha; Guri Giaever; Corey Nislow; Patrick Flaherty; Xuewen Pan; Gabriele Vargas Cesar; Patricia de Melo Tavares; Susana Frases; Kildare Miranda; Marcio L Rodrigues; Chiara Luberto; Leonardo Nimrichter; Maurizio Del Poeta
Journal:  mBio       Date:  2015-06-23       Impact factor: 7.867

View more
  1 in total

Review 1.  Advances in Antifungal Drug Development: An Up-To-Date Mini Review.

Authors:  Ghada Bouz; Martin Doležal
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.